MX2025002312A - Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina - Google Patents
Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabinaInfo
- Publication number
- MX2025002312A MX2025002312A MX2025002312A MX2025002312A MX2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapies
- tolinapant
- cedazuridine
- decitabine
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374137P | 2022-08-31 | 2022-08-31 | |
| PCT/IB2022/060652 WO2024047394A1 (en) | 2022-08-31 | 2022-11-04 | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025002312A true MX2025002312A (es) | 2025-04-02 |
Family
ID=84359488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002312A MX2025002312A (es) | 2022-08-31 | 2025-02-26 | Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082286A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4580635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025529240A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250053870A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022476674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3266274A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025002312A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202410893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024047394A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-11-04 JP JP2025513127A patent/JP2025529240A/ja active Pending
- 2022-11-04 TW TW111142283A patent/TW202410893A/zh unknown
- 2022-11-04 AU AU2022476674A patent/AU2022476674A1/en active Pending
- 2022-11-04 KR KR1020257007164A patent/KR20250053870A/ko active Pending
- 2022-11-04 CA CA3266274A patent/CA3266274A1/en active Pending
- 2022-11-04 WO PCT/IB2022/060652 patent/WO2024047394A1/en not_active Ceased
- 2022-11-04 EP EP22805975.4A patent/EP4580635A1/en active Pending
-
2023
- 2023-08-30 US US18/458,884 patent/US20240082286A1/en active Pending
-
2025
- 2025-02-26 MX MX2025002312A patent/MX2025002312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4580635A1 (en) | 2025-07-09 |
| WO2024047394A1 (en) | 2024-03-07 |
| AU2022476674A1 (en) | 2025-04-17 |
| KR20250053870A (ko) | 2025-04-22 |
| JP2025529240A (ja) | 2025-09-04 |
| TW202410893A (zh) | 2024-03-16 |
| US20240082286A1 (en) | 2024-03-14 |
| CA3266274A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| EP4616902A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| MX2025005315A (es) | Celulas t para usarse en el tratamiento de una enfermedad o afeccion | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| PH12023552792A1 (en) | Combination therapies for the treatment of cancer | |
| MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2023006551A (es) | Tratamiento de las convulsiones refractarias. | |
| MX2024015041A (es) | Fitusiran para el tratamiento de la hemofilia a y b | |
| WO2021041716A3 (en) | Therapeutic editing to treat cardiomyopathy | |
| EP4623999A3 (en) | Sotorasib for use in the treatment of cancer | |
| MX2023006651A (es) | Tratamiento de la hemofilia con fitusirán. | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies | |
| MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| MX2025015461A (es) | Tratamiento combinado | |
| MX2024005589A (es) | Combinaciones de lurbinectedina y atezolizumab. |